

EU Declaration of Conformity

In accordance with EU Regulation 2017/746 of the European Parliament and of the Council of 5 April 2017 on *in vitro* diagnostic medical devices.

Manufacturer: Ventana Medical Systems Inc.

1910 E Innovation Park Drive Tucson, AZ 85755, USA

Single Registration Number (SRN)

Manufacturer:

US-MF-000016993

Authorized Representative: Roche Diagnostics GmbH

Sandhofer Strasse 116

68305 Mannheim

Germany

Single Registration Number (SRN)

Authorized Representative:

DE-AR-00006262

This declaration is issued under the sole responsibility of Ventana Medical Systems Inc.

Product Information

Part Number:	Product Name:	Basic UDI-DI:
05277990001 (alternative P/N: 790-2223)	CONFIRM anti-Progesterone	761333601236AB
50 tests	Receptor (PR) (1E2) Rabbit	
05278392001 (alternative P/N: 790-4296)	Monoclonal Primary Antibody	
250 tests		

Intended Purpose: CONFIRM anti-Progesterone Receptor (PR) (1E2) Rabbit Monoclonal (IgG)

Primary Antibody is intended for laboratory use in the qualitative detection of progesterone receptor (PR) antigen in sections of formalin-fixed, paraffinembedded tissue on a VENTANA automated slide stainer with VENTANA detection kits and ancillary reagents. CONFIRM anti-PR (1E2) antibody is directed against an epitope present on human progesterone receptor protein located in the nucleus of PR positive normal and neoplastic cells. CONFIRM anti-PR (1E2) antibody is indicated as an aid in the management, prognosis, and prediction of therapy outcome of breast carcinoma. This product should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information, and proper controls. Prescription use only. This antibody is intended for in vitro diagnostic (IVD) use.

Risk Class: Class C

Common Specifications: Not applicable as no Common Specifications exist for the concerned

devices.



Name, Address and Identification number of the Notified Body:

TÜV SÜD Product Service GmbH (No. 0123) Ridlerstraße 65 80339 MÜNCHEN Germany

Conformity Assessment was established through the procedure described in Annex IX of EU Regulation 2017/746, including an assessment of the Technical Documentation as described in Annex IX, Chapter II. This declaration is supported by the following certificate(s):

EU Quality Management System Certificate: V12 096981

Conformity of the product with EU Regulation 2017/746 and other applicable EU legislation has been established.

On behalf of Ventana Medical Systems Inc.

Place: Tucson, AZ 85755, USA Place: 1

Date: 26-Jan-2022

Jeff Boone

DocuSigned by:

Jett Boone

Site Head of Quality Function

Place: Tucson, AZ 85755, USA

Date: 31-Jan-2022

Ben Curson

Benjamin Curson

Site Head of Regulatory Affairs Function